141 related articles for article (PubMed ID: 25190612)
1. Update on obinutuzumab in the treatment of B-cell malignancies.
Illidge T; Cheadle EJ; Donaghy C; Honeychurch J
Expert Opin Biol Ther; 2014 Oct; 14(10):1507-17. PubMed ID: 25190612
[TBL] [Abstract][Full Text] [Related]
2. Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy.
Al-Sawaf O; Fischer K; Engelke A; Pflug N; Hallek M; Goede V
Drug Des Devel Ther; 2017; 11():295-304. PubMed ID: 28182141
[TBL] [Abstract][Full Text] [Related]
3. Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab.
Smolej L
Pharmgenomics Pers Med; 2015; 8():1-7. PubMed ID: 25691812
[TBL] [Abstract][Full Text] [Related]
4. Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma.
Herting F; Friess T; Bader S; Muth G; Hölzlwimmer G; Rieder N; Umana P; Klein C
Leuk Lymphoma; 2014 Sep; 55(9):2151-5160. PubMed ID: 24304419
[TBL] [Abstract][Full Text] [Related]
5. Obinutuzumab for relapsed or refractory indolent non-Hodgkin's lymphomas.
Gabellier L; Cartron G
Ther Adv Hematol; 2016 Apr; 7(2):85-93. PubMed ID: 27054024
[TBL] [Abstract][Full Text] [Related]
6. Tolerability of obinutuzumab therapy in patients with rituximab-relapsed/refractory B-cell malignancies - a retrospective single center cohort study.
Pirich T; Zwickl-Traxler E; Pecherstorfer M; Singer J
Oncotarget; 2018 Jul; 9(52):29944-29956. PubMed ID: 30042825
[TBL] [Abstract][Full Text] [Related]
7. Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy.
Pierpont TM; Limper CB; Richards KL
Front Oncol; 2018; 8():163. PubMed ID: 29915719
[TBL] [Abstract][Full Text] [Related]
8. Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors.
Peters S; Angevin E; Alonso-Gordoa T; Rohrberg K; Melero I; Mellado B; Perez-Gracia JL; Tabernero J; Adessi C; Boetsch C; Watson C; Dal Porto J; Dejardin D; Del Nagro C; Nicolini V; Evers S; Klein C; Leutgeb B; Pisa P; Rossmann E; Saro J; Umana P; Charo J; Teichgräber V; Steeghs N
Clin Cancer Res; 2024 Apr; 30(8):1630-1641. PubMed ID: 38319672
[TBL] [Abstract][Full Text] [Related]
9. New agents for the treatment of lymphoid leukemia and lymphoma: focus on recent FDA approvals.
Stancu AL; Smith MR; Almasan A
Discoveries (Craiova); 2014; 2(1):. PubMed ID: 26280017
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of safety outcomes with transitioning obinutuzumab from standard rate to short duration infusion in patients with chronic lymphocytic leukemia.
Fleck C; Karabinos A; Cook A; Moore DC; Jacobs R
Leuk Lymphoma; 2024 Apr; ():1-2. PubMed ID: 38646879
[No Abstract] [Full Text] [Related]
11. A rescue approach in refractory diffuse large B-cell lymphoma with obinutuzumab-redirected cytokine-induced killer cells: a first-in-human case report.
Elice F; Sommaggio R; Cappuzzello E; Riva M; Tisi MC; Bernardi M; Bozza A; Catanzaro D; Chieregato K; Merlo A; Giaretta I; Pieta AD; Krampera M; Visco C; Trentin L; Visentin A; Tosetto A; Astori G; Rosato A
Haematologica; 2024 May; ():. PubMed ID: 38721751
[TBL] [Abstract][Full Text] [Related]
12. Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody.
Goede V; Klein C; Stilgenbauer S
Oncol Res Treat; 2015; 38(4):185-92. PubMed ID: 25877943
[TBL] [Abstract][Full Text] [Related]
13. Obinutuzumab in hematologic malignancies: lessons learned to date.
Illidge T; Klein C; Sehn LH; Davies A; Salles G; Cartron G
Cancer Treat Rev; 2015 Nov; 41(9):784-92. PubMed ID: 26190254
[TBL] [Abstract][Full Text] [Related]
14. Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.
Robak T
Expert Rev Hematol; 2014 Dec; 7(6):841-57. PubMed ID: 25249370
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib, obinutuzumab, idelalisib, and beyond: review of novel and evolving therapies for chronic lymphocytic leukemia.
Chung C; Lee R
Pharmacotherapy; 2014 Dec; 34(12):1298-316. PubMed ID: 25355689
[TBL] [Abstract][Full Text] [Related]
16. Past, present and future role of chlorambucil in the treatment of chronic lymphocytic leukemia.
Goede V; Eichhorst B; Fischer K; Wendtner CM; Hallek M
Leuk Lymphoma; 2015 Jun; 56(6):1585-92. PubMed ID: 25219593
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure-Response in CLL.
Gibiansky E; Gibiansky L; Carlile DJ; Jamois C; Buchheit V; Frey N
CPT Pharmacometrics Syst Pharmacol; 2014 Oct; 3(10):e144. PubMed ID: 25353187
[TBL] [Abstract][Full Text] [Related]
18. Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL).
Komarova NL; Burger JA; Wodarz D
Proc Natl Acad Sci U S A; 2014 Sep; 111(38):13906-11. PubMed ID: 25201956
[TBL] [Abstract][Full Text] [Related]
19. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study.
Goede V; Fischer K; Engelke A; Schlag R; Lepretre S; Montero LF; Montillo M; Fegan C; Asikanius E; Humphrey K; Fingerle-Rowson G; Hallek M
Leukemia; 2015 Jul; 29(7):1602-4. PubMed ID: 25634683
[No Abstract] [Full Text] [Related]
20. Progress in the treatment of elderly/unfit chronic lymphocytic leukemia patients: results of the German CLL-11 trial.
Molica S
Expert Rev Anticancer Ther; 2015 Jan; 15(1):9-15. PubMed ID: 25479582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
